3SOF

I had been preparing to write my GMAT, for those of you who were wondering where I had been. I am pleased to say I wrote my test today and I scored 650(84% percentile).

MarketMakerz is going to business graduate school!!!YAY!!!  

As for GLIF...What can I say? Typical sell on news by MOMO players. But guess what? Those who know the potential have been picking up on MOMO weakness all along.

An intresting observation was on the day that GLIF dropped to a low of 0.033, buy volume(6 mil) was roughly equal to sell volume(6.8Mil).

The news was not of surprise. It just goes to show this company unlike many penny stocks is REAL. Has a REAL product. And has a management team that is second to none in penny land.

This news was also just the tip of an iceberg. Southeast Asia and the Middle East are their next targets. When they establish their base in these places with a solid cash flow...Top that with FDA approval...Oh boy watch out!

It's very scary to think about the potential of all the things that could come up our way!!!




Cheerz to everyone here reading this one. GLIF is GOLD! Keep digging for more of it!

yeap

Technical Analysis for close on Nov 04,2005:

Beautiful close at HOD for Friday Nov 4th. As I said before it is a safe bet to load up on the bottom of the red and blue channel and unload on top of the channel if you are a day trader. If you have longer time frames you should be loading up regardless.

Candlestick Analysis:
Today a Long White Candlestick was formed. The Long White Candlestick is a signal indicating strong buying pressure. The Long White Candlestick is a single candlestick pattern and it is not reliable as such. It reflects only one day's trading. It may show continuation of a trend as well as a possible reversal.You should continue to be holding GLIF based on the previous Buy signal made back 4 days ago.
______________________________

I am out of here.

Have a great weekend everyone.

Eggaman, you made my job that much easier. Appluad!!!

Securing the funds needed for its operations was the biggest concern of the management over the summer. Now, most often you see penny stocks have difficulty rasing cash for their operations and to face this problem they start issuing new stocks.

The situation was different here at GLIF land. Management's solid connections and their solid product line gave GLIF little problem rasing the needed cash through a bunch of investors(New Millennium Capital Partners II, LLC, AJW Qualified Partners, LLC, AJW Offshore, Ltd. and AJW Partners, LLC) by  sale of $2,000,000 in callable secured convertible notes (the Notes) and stock purchase warrants (the Warrants) to buy 7,692,308 shares of our common stock.

Not rocket science.

This management team knows what they are doing. Unlike many other penny stocks.

Looking good so far...

So far the Channel I provided last night has proved to be the key to today's movements. Not bad!

It will hold its support line. It's your call whether you would want to day trade it or not. Personally i think it is a safe play within the red and blue line channel i drew on the first chart.

Forgot to lock the thread before. This thread will be one way communication only. If you want to get to me PM me.

Technical Analysis for close on Nov 3, 2005 :
As you could see from the chart we have developed a rising channel. If you are a daytrader chances are you could make a buck or two if you try to load up on the bottom of this channel and sell on top of it.

A news could change this strong channel's direction.

Candlestick Analysis:

Today a  Long Black Candlestick was formed. This generally is a bearish indicator but it needs confirmation. Based on candlesticks you should wait for confirmation of a sell signal. Confirmation is provided with strong volume on the down side (In other words breaking through the channel drawn on the first chart).


I dont personally rely on technicals ( I am long on GLIF with a very large position; Large for penny stocks). As I have mentioned before my initial sell order is set to sell half of my position at $0.25. I will hold on to the other half and unload gradually depending on the direction company takes.

I post this interview with the CEO again for those who missed it the first tme i posted it here (interview was carried out in March of 2005. It could be used to give you a better picture of this company).
_______________________________________
BIO:
Stan Yakatan, MBA, is Chairman and CEO of Grant Life Sciences, Inc.  He has over 30 years experience as a chief executive, entrepreneur, and operational manager for biotech and medical companies.  He served as an executive and in several instances as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch.   He has founded or co-founded more than 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He sits on the board of directors of several public and private companies, and has served as an advisor to a number of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada) as well as to the governments of Australia and Canada.

Company Profile:
Grant Life Sciences, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. These screening tests analyze blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually world-wide. There are more than 120 million cervical screening tests administered annually in the United States and Europe. But more than 120 million eligible women 20+ years old in developed nations still do not get Pap smears. Globally, more than 1.7 billion women over the age of 20 do not undergo any cervical cancer screening.

Question: Mr. Yakatan, please give us a little background on Grant Life Sciences.
Mr. Yakatan: "The technology behind Grant was begun over two years ago when a scientist from China, working with the University of Utah, teamed up with Dr. Mark Rosenfeld to do some work in cervical cancer. As a result of their initial activities they filed a patent for the use of various amino acids to identify the antibodies that surface when a woman has cervical cancer. They looked at blood and body fluids as opposed to the traditional Pap smear. With their patent applied for, they connected with a local entrepreneur named Michael Ahlin, who today is our Vice President of Development and a Director with Grant, and he provided some initial capital. When the venture capital route proved to be too dilutive, they began working with a brokerage firm here in New York to facilitate a reverse merger with a publicly traded entity to raise capital, which was done quickly and successfully. Then I and several others with a lot of experience were recruited to be the management team, which is where we are today."


Question: What is it that your test can do that others can't?
Mr. Yakatan: "Normally to check cervical cancer, women generally go for a Pap smear, which is considered in the industry to be highly inaccurate. Currently, there is no simple test, where you can just take the blood from a patient and determine by measuring antibodies in the blood whether cervical cancer or cervical cancer pre-cursors are present.  We have developed what we believe is the first blood test that does this, and the initial data is extremely compelling."


Question: What is it that your scientists have discovered that hasn't been done before?
Mr. Yakatan: "We've discovered in the literature five or six attempts to identify precursors to cervical cancer through various methods. What our group did is developed a series of oncogenic amino acid sequences.  We have characterized them in a way that can be utilized in a standard screening test where the amino acid sequences would truly identify the presence of cervical cancer or cervical cancer pre-cursors in blood or bodily fluid samples.  I don't think it's any trick or black magic; I think that we've just been able to do a lot of laboratory work in terms of screening hundreds of different amino acid sequences. We have discovered that a test that we would make for the U.S. market may have a different sequence than a test that we would make for the Indian or Chinese markets because the makeup of the oncogenes that show cervical cancer activity vary in different geographical areas of the world. What we are doing now is working very closely with a partner, Allogen, which is a part of the Cleveland Clinic Foundation, in trying to characterize all of these amino acids. We think that within three to six months, we'll be able to have our initial characterization completed and a product essentially ready to go into clinical trials, both in the United States and in other places in the world."


Question: What's the process and about how long does it take?
Mr. Yakatan: "We think that the longest process for us is the amino acid characterization.  What we want to do is a sample collection before we go to any regulatory agency; we then test these samples from thousands of patients in what we call institutional review board programs. We have a few of them already set-up at USC, UCLA, Johns Hopkins and a local hospital in Utah. We've begun an active program to identify 4,000 samples within a six-month period to do the characterization program. So we think it may take two to three months to characterize the amino acids; another four to six months to do the sample collection and process those samples. Then we would begin a regulatory submission. If we are lucky, and I say lucky is the key word, we will be able to file a 510K with the US FDA (Food and Drug Administration) as an adjunct to Pap smears and that process could take three to six months. However, if we have to do a complete product disclosure process, it could take as much as eighteen months to two years. We believe that in the rest of the world we can get a swift approval of our rapid test. We think that once the nine months to a year of laboratory development time and amino acid characterization is completed, we could put a product on the market outside of the U.S. within a year."


Question: Where do you go from here?
Mr. Yakatan: "We're continuing to characterize the amino acid sequences to make sure that we have the right sequences. We are currently developing two products, the first of which is an ELISA (Enzyme Linked Immunosorbent Assay) test which we would file as an adjunct in the United States through the FDA.   The second is a rapid test-- a point-of-care test that would be low cost and could serve the more than 1.7 billion women outside of the United States and Europe who normally don't get any type of cervical screening.  This probably accounts for over half the world and can be due to religious or economic reasons or just some type of taboo where women don't feel comfortable getting a cervical exam from a physician."


Question: Is there a market for rapid test in the United States?
Mr. Yakatan: "The issue is how imbedded the Pap smear is in the U.S. and whether or not we would  be able to get the community to accept a blood test after 50 years of doing traditional Paps. In our early discussions with people in the marketplace as well as the FDA, it's been suggested to us that the best way to get a new cancer test approved is as an adjunct. So, we think that strategically it makes sense to develop an adjunct test for the U.S. market and develop an inexpensive rapid test for the global market."


Question: Do you have enough funding going forward?
Mr. Yakatan: "Our initial capitalization was through a reverse merger were we raised about $1.8 million total. We are now looking for another $3 to $5 million and we think that with that second round of financing, we should be able to complete all of the pre-market activities and get the products on the market."


Question: What is the market potential for your test?
Mr. Yakatan: "In the United States, there are 60 million women who receive routine Paps of some form. Out of that, about 20% get false positives or false negatives, which lead to about 9 million colposcopy procedures; of that, 7 million turn out to be negative. So, we want to focus on an adjunct test where we could reduce the number of colposcopies and save the American health care system over $1.5 billion annually, not to mention eliminating the unnecessary mental anguish some of the false negatives create for our mothers and daughters.  We think that the U.S. market alone is about 7 to 10 million tests annually at $25.00 to $30.00 a test.  As I said before, the world market outside of the U.S. consists of over 1.7 billion women that have never been screened. We think that for those women, we can develop a test that would cost under $5.00, which is our goal. Then, we would ultimately put that same test on the market in the United States. I was retired for many years from being a CEO in biotech and when the opportunity came to me to look at a novel patented technology that serves an unmet market of over 1.7 billion people, that was enough excitement to get me to come back to work again."


Question: Can you give us an idea of what you are up against in the medical community to gain acceptance for your new approach?
Mr. Yakatan: "The issue is that Dr. George Papanicolaou developed this test about 68 years ago.  If you talk to any medical pathologist they will tell you that this is an archaic test that is highly inaccurate. However, it has become well accepted in the community. It is completely reimbursed by the insurance community and if they get a false positive, the patient would then go for a colposcopy, another reimbursable procedure. Unfortunately false negatives are more problematic of course. Just to give an idea of how well entrenched the Pap smear is in the United States, there was a recent article in the N.Y. Times that pointed out that about 12% of the women receiving Pap smears have had hysterectomies. They don't even have a cervix any longer to take a Pap sample from!.  Our new medical director, David Bolick, MD, FCAP, MIAC, is one of the most well-known spokesmen in the world for the replacement of the Pap smear. It's one of the reasons we brought David into our fold and he will be speaking at meetings all around the United States on our technology."


Question: What about going directly to women and women's groups?
Mr. Yakatan: "We plan to do exactly that. One of our founders, Michael Ahlin, has been given the responsibility to look into women's groups around the United States and see if we can generate support. It is common knowledge among the medical community that the current process of the cervical examination a very negative and highly invasive experience."


Question: Could you address potential investors; what should they know about the background of the management and the company that would make them want to invest it Grant Life Sciences?
Mr. Yakatan: "We have a very experienced management team. I have 35 years of experience in the biotech world. There are people who consider me part of the old guard. I've run companies like this before and much of the investment community knows who I am and my track record. We have a CFO, John Wilson, who has a similar background and a strong financial pedigree. He was senior banker at Credit Suisse First Boston and prior to that, served as CFO for Hardee's Food Systems, Perrier USA and Bell Canada International.  John has served on numerous boards, both public and private. In many of these cases, he was their CFO and did tremendous things for them. We have someone who has 20 years experience in product development ready to join us. In diagnostics we are working with the man who actually developed the rapid test program for Hoffmann-La Roche in terms of developing our rapid test program. We are working directly with the cancer center in China and that's important because China has the highest incidence of cervical cancer in the world. There are approximately 100,000 deaths there a year because of the lack of screening and we are the only company that is working directly with the center.  One of our founders, and a continuing consultant to the Company, is a scientific advisor to the center in China and has about ten years experience in the Chinese market. We brought on as a consultant to the company a former high level executive at the National Cancer Institute and he is working with us in terms of government funding and grants.  We believe that within the next 2 to 3 months we will solidify a major relationship with an institute in the United States that has the largest W.H.O. grant in the world for this type of work. So, we think that the combination of the experience of the management team, plus the market size and viability of the market are excellent opportunities for investors."


Question: In closing, could you tell us how long do you anticipate it will take for acceptance?
Mr. Yakatan: "The acceptance will be very rapid. We've actually had discussions with the Gates Foundation and other organizations that specialize in finding funding for third world countries and we are just in the early stages of those discussions. In reality, the company as it exists now is essentially two months old. The management team has worked very closely with the founders to pull together all the work that has been done to date and that has been a harmonious relationship."

Here i am oppening a whole new thread where i will be posting my holdings and the analysis that comes with my picks.

Current Holdings:

Grant life Sciences.               GLIF.OB: 300,000 shares.   Average Entry Price: $0.019

BCON Power Corp                 BCON:10,000 shares          Average Entry Price: $2.00

UEX Corporation (uranium)    UEX.TO:8,000 Shares         Average Entry Price: $2.3(CND)

I also trade Options but i am not going to discuss that here as options will have relatively shorter time frames and they are out of the scope and purpose of this thread. However, if you feel like asking me anything on Options feel free to PM me.

Long term Bullish on Gold
Long term Bullish on Oil, Uranium and renewable energys
Short term Bullish on Pharma
Long term Bearish on Real estate



______________________________________________________

Important Note 1: This thread will be locked until further notice.
Important Note 2: If you want me to take a position on a stock and do a DD on that specific stock PM me. If I see potential I would let you know and start posting my DD on it.

Quote from: wrangler on November 03, 2005, 10:31:13 AM
Hi 3SOF trading community
Seemed like to me it was stalling around .060 so I decided to sell GLIF all shares @.059. Still it was over 50% profit for me. I'm happy taking that kind of profit.
eliteG ,you are one mean,lean trading machine.
Thanks a million
Good luck to all still holding

Good trade. Though i think you are set to lose the biggest leg of the race. I t6hink it would have been wise to keep some of that position. MMz want retail shares.

Quote from: eliteG on November 03, 2005, 09:23:35 AM


I guess what I'm trying to say is I'm worried about everyone selling at the same time.

With the kind of action I saw yesterday before the close I am pretty sure MMz would be glad if we all sold at once

Quote from: somebody041 on November 02, 2005, 10:00:42 PM
Wow, nice eye.  That's a pretty reassuring sign.

Reassuring it is!

The great thing about it is that tommorow is Thursday NOT friday.

HEADS UP!!!AWAYYYYYY WE GO!!!

Quote from: runforthedoor on November 02, 2005, 09:40:34 PM
  MM...OK...I understand....and agree with you...on the 200 shares too...I have heard and seen those numbers work that way before. So, are you saying I'm old?  I am somewhat old.  Is that pic really you...if so, I'll applaud your smile.  I'm a little applaud happy today. 

Hahaha...no brother! I maybe younger age-wise but i am pretty sure you are just as young in heart.

BTW that pic is not me! Dont get your hopes high lol! 

PS: I gave you the last applaud of the night. I better watch out for the applaud police. I am pretty sure this last one i gave you was illegal ...It's ok though since GLIF is doing good and most on this board own GLIF...So everyone should be happy!